v3.26.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Revenue:    
Total revenue $ 20,757,000 $ 19,097,000
Costs and expenses:    
Cost of revenue 22,926,000 23,539,000
Selling, general and administrative (including stock-based compensation) 12,265,000 38,154,000
Total costs and expenses 35,191,000 61,693,000
Operating loss (14,434,000) (42,596,000)
Other income (expense):    
Interest income 19,000 238,000
Interest income on note receivable, related party 32,000 102,000
Dividend income 20,000
Other 11,000 218,000
Interest expense (266,000) (283,000)
Foreign Currency Translation Adjustment (6,000)
Gain on extinguishment of debt 595,000
(Loss)/gain on equity method investment (16,000) 1,000
(Loss) gain on investments (807,000) 224,000
Impairment of investment (782,000)
Impairment of intangible assets (600,000)
Impairment of real estate assets (2,420,000) (7,288,000)
Provision for loan losses (3,691,000)
(Loss)/gain on sale real estate assets (9,622,000) 165,000
Loss from operations before income taxes (27,488,000) (53,698,000)
Income tax benefit (8,000)
Net loss (27,488,000) (53,706,000)
Loss from operations attributed to noncontrolling interest 3,559,000 6,810,000
Net loss attributable to DSS common stockholders $ (23,929,000) $ (46,896,000)
Loss per common share attributable to common stockholders    
Basic $ (2.66) $ (6.63)
Diluted $ (2.66) $ (6.63)
Shares used in computing loss per common share:    
Basic 8,991,425 7,072,377
Diluted 8,991,425 7,702,377
Printed Products [Member]    
Revenue:    
Total revenue $ 18,085,000 $ 16,107,000
Rental Income [Member]    
Revenue:    
Total revenue 1,236,000 1,792,000
Commercial Lending [Member]    
Revenue:    
Total revenue 45,000 226,000
Commission [Member]    
Revenue:    
Total revenue 1,353,000 972,000
Biotechnology [Member]    
Revenue:    
Total revenue $ 38,000